A view of Baguang International Biovalley.

1. Leading Enterprises

Dapeng New District is actively cultivating a dynamic biopharmaceutical industry, leveraging the combined strengths of its specialized parks—including the Life Sciences Industrial Park, the Marine Biotechnology Park, and the Baguang International Bio-Valley—to build a solid foundation for high-quality growth in life sciences and medical innovation. Through strategic clustering, the district has attracted a number of established biopharmaceutical companies such as Shenzhen Green Source Biotechnology Co., Ltd. and Shenzhen Zifu Pharmaceutical Co., Ltd. In September 2023, Shenzhen ZeYi Cell Therapy Group officially launched operations in Dapeng, quickly reaching the scale required for inclusion in national statistical records.

2. Innovation Platforms

The district is home to major innovation hubs including the National Gene Bank—one of the world’s leading comprehensive biological and genetic resource repositories—and the Shenzhen Antibody Drug Pilot Testing Base. Dapeng is also advancing the development of the Agricultural Genomics Research Center, focusing on complex genome analysis, whole-genome design breeding, synthetic genomes, and artificial chromosomes. These initiatives support original breakthroughs in fields such as bio-breeding and biosafety.

3. Industrial Parks

Dapeng currently has eight purpose-built industrial parks ready to accommodate biomanufacturing enterprises, with a combined floor area of 1.12 million square meters. An additional seven industrial parks—including the Baguang Incubator—are under construction and will provide another 650,000 square meters of space for industries including biopharmaceuticals upon completion.

4. Regulatory Approvals & Talent Development

As of 2023, five enterprises in the district had collectively secured 19 pharmaceutical-related regulatory approvals. The district also hosts two elite research teams associated with Nobel laureates Watson and Marshall, enhancing its capacity for cutting-edge scientific innovation.

5. Unique and Scarce Resources

In September 2023, Shenzhen Zeyi Clinic established its new headquarters in Dapeng. The facility includes a Cell Therapy Research Institute, a Nobel Laureates & Leading Scientists Innovation Center, a diagnostics laboratory, the largest cryogenic cell storage facility in the Greater Bay Area, and a ZeYi outpatient clinic. Additionally, the Dapeng People's Hospital—designed as a top-tier (Class A, Grade 3) general hospital—has topped out its main structure and is expected to be completed by the end of 2024. With 2,000 planned beds, it will integrate medical services, research, education, and public health, serving as a key platform for R&D collaboration and commercialization for gene and cell therapy enterprises.